Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Michel Sadelain

Carl June

Michel Sadelain, of Memorial Sloan Kettering Cancer Center, and Carl June, of University of Pennsylvania, are two of the recipients of the 2024 Breakthrough Prize in Life Sciences for the development of chimeric antigen receptor T-cell immunotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Wugen Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, announced it will initiate a phase II study in the first quarter of 2025 for the company’s potential first-in-class, investigational, anti-CD7 CAR T-cell therapy, WU-CART-007, in patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login